Literature DB >> 31225766

Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status.

Amir Behdad1, Craig S Boddy2, Angela J Fought3, Timothy Taxter1, Marissa K Falkiewicz4, Emily Ayers4, Qing C Chen1, Yi-Hua Chen1, Reem Karmali2, Barbara Pro2, Jane N Winter2, Daniel J Landsburg4, Leo I Gordon2, Jason B Kaplan2.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) transformed from follicular lymphoma (FL) (tDLBCL) has been traditionally associated with an aggressive course, but more recent studies have shown longer survivals. The clinical significance of concurrent FL at the time of diagnosis of DLBCL (cDLBCL/FL) is less clear. We compared outcomes of tDLBCL, cDLBCL/FL, and de novo DLBCL (dDLBCL) and then evaluated the impact of double hit (DH) rearrangements (MYC with BCL2 and/or BCL6) in these subgroups' outcomes. The progression free survival (PFS) and overall survival (OS) were not significantly different among the three groups (dDLBCL, tDLBCL, and cDLBCL/FL). The effect of DH on survival was then analyzed in two subgroups: (1) dDLBCL and (2) tDLBCL + cDLBCL/FL. PFS and OS were significantly shorter in lymphomas with DH in each of these two subgroups. We conclude that DH status drives outcomes in all DLBCLs, regardless of their transformation status.

Entities:  

Keywords:  MYC ; Transformed follicular lymphoma; diffuse large B-cell lymphoma; double hit lymphoma; high grade B-cell lymphoma

Year:  2019        PMID: 31225766     DOI: 10.1080/10428194.2019.1622099

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.

Authors:  Zhenjie Qu; Tingting Zhang; Fenghua Gao; Wenchen Gong; Yaoli Cui; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Bin Meng; Xiubao Ren; Lanfang Li; Xianhuo Wang; Huilai Zhang
Journal:  Biomed Res Int       Date:  2022-05-24       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.